Abstrak
Recommended treatments of acute asthma attack recently are β 2 -agonist bronchodilator inhalation and glucocorticoid systemic for patients, which do not response to bronchodilator only. 1 Adding systemic corticosteroid in acute asthma attack has been proven to decrease number of in-patient, significantly decrease incidence of acute asthma exacerbation, and increase lung function after exacerbation compared to bronchodilator only. 1, 2 It is said that long-term systemic corticosteroid is safe, but has potential of side effects, especially for patients with recurring attacks. Systemic corticosteroid intravenously on the other hand does not always easy to be administered. 3 The goals of asthma management do not only prevent and treat asthma exacerbation but also chronic asthma. Phormoterol fumarate dihydrate is a long acting β 2 -agonist with rapid onset. The roles of β 2 -agonist are increasing both for acute and chronic/stable asthma. The development of devices for delivering asthma drugs such as metered dose inhaler (MDI), MDI + with spacer, rotahaler, autohaler, turbuhaler, diskhaler, or easyhaler are more popular in recent year. Inhalation devices can produce small dose, minimum systemic side effects, and place the drug right on target cells or location of inflamation. 4 Budesonide is a glucocorticoid, which developed for topical anti-inflamation, (e.g. asthma and rhinitis). Inhalation corticosteroid has high topical-systemic ratio effect and shows very good result in controlling asthma. This is explained by a combination of a relatively high local anti-inflamatory effect, extensive first pass hepatic degradation of orally absorbed drug (85-90%) and low potency of metabolites. 5 In the previous study budesonide/phormoterol combination showed ability as reliever which can release airway obstruction in 4 minutes. 6 Gibson et al. 7 stated that after 6 hours of budesonide inhalation, there was significant changes in airway reactivity, 12% eosinophile degradation, and 4% increasing of force expiration volume in 1 second (FEV1). Beside anti-inflamatory feature, corticosteroid has also β 2 mimetic action which work 2-4 hours after delivery and increased β 2 receptor regulation. Inhaled corticosteroid has high poten of topical effect with minimal systemic effect, and has shown very good results in controlling asthma in children and adults. 4 
METHODS
This was an open randomized clinical trial on 76 moderate acute asthma patients, which came to emergency unit or asthma clinic in Persahabatan Hospital. This trial has been proved by ethical committee of University of Indonesia Medical Faculty. We started this study on April 2005 until July 2005. Seventy-six subjects enrolled this study until completed.
The inclusion criteria were moderate acute asthma, male or female of 12-60 years old with asthma score 8-12 as seen in table 1, subject could perform peak expiratory flow maneuver, and gave written agreement to enroll this study.
The patients were given information about the aim of this study, agreed to enroll until completed, stated orally and sign informed consent paper. Moderate asthma acute patients, which met with inclusion criteria and agreed to enroll this study, were divided randomly into 2 groups. We gave dry-powder inhalation of phormoterol/budesonide combination to the treatment group with doses of 4.5/160 g (T-group). Repeated inhalation were administered at 20 and 40 minutes. Control group was given nebulized of 2.5/0.5 mg salbutamol/ipratropium bromide combination (N-group). Nebulization was administered with jet nebulizer (merk DeVILBISS). Repeated inhalation were performed at 20 and 40 minutes. We did physical examination and wrote all data collected.
Evaluations were performed on breathless, talking, allertness, respiratory rate, heart rate, respiratory muscle retraction, wheeze, and peak expiratory flow rate (PEFR). Peak expiratory flow rate was measured with peak flow meter mini Wright (Airmed, Clement Clarke International Ltd. London. England). The highest value was taken among three times measurements with difference among values not more than 5%. Those values were then compared to normal PEFR predicted values of Indonesian people from Pneumobil Indonesia Project. 9 Peak expiratory flow rates were measured at first time visit before initial therapy then at 5, 7, 10, 15, 30 60, 120, 180, 240, 300, and 360 minutes. These result then were scored according to table 1.
We used asthma-scoring table to evaluate improvement of the attack. Score were noted before initial treatment then 20, 40, 60, 120, 180, 240, 300, 360 minutes. Side effects, which would be expected, were tremor, palpitation, hoarseness, soar throat, and tachycardia. If there were side effects, we scored 1 and 0 if there were not. If there were fever, or color changing sputum, or leucosite > 10.000/m 3 , or there were infiltrates in chest x-ray, then patients were given antibiotics and excluded from trial. Oxygen 3-4 L/min was administered. At the end of trial patients with incomplete response and asthma-scoring > 4, would be treated in the emergency unit. These patients continued enrolling the study and their data would be evaluated and tested. Total cost was counted based on the cost in Persahabatan Hospital. 
RESULTS
Seventy-six subjects of moderate asthma attack were divided randomly into two groups, T-group and Ngroup, 38 in each group. All subjects enrolled trial until completed.
Distribution of sex was 29 (76.3%) female and 9 (23.7%) male subjects in T-group, while 28 (73.7%) female and 10 (26.3%) male subjects in N-groups. These data was not statistically significant.
Confounding factors such as ages, highs, weights, PEFR predicted values, and initial PEFRs, were not statistically significant.
Breathless
The difference of breathless between the two groups was not statistically significant. Of T-group 5 (13.2%) subjects with score 1 and 33 (86.8%) subjects with score 2, while of N-group 6 (15.8%) subjects with score 1 and 32 (84.2%) subjects with score 2, P value > 0.05 (P = 1.000). Until the end of observation (360 minutes) there were no subjects with breathless complain, figure 1. T0=∑T subjects with score 0; T1=∑T subjects with score 1; T2=∑T subjects with score 2; T3=∑T subjects with score 3; N0=∑N subjects with score 0; N1=∑N subjects with score 1; N2=∑N subjects with score 2; N3=∑N subjects with score 3.
Talking ability
At initial observation, there was no significant difference of talking ability between two groups. Of T-group 9 (23.7%) subjects with score 1 and 29 (76.3%) subjects with score 2, while of N-groups 4 (10.5%) subjects with score 1 and 34 (89.5%) subjects with score 2. P value > 0.05 (P = 0.223). Until the end of observation (360 minutes), all subjects could talk normally, figure 2. T0=∑T subjects with score 0; T1=∑T subjects with score 1; T2=∑T subjects with score 2; T3=∑T subjects with score 3; N0=∑N subjects with score 0; N1=∑N subjects with score 1; N2=∑N subjects with score 2; N3=∑N subjects with score 3.
Alertness
All subjects in both groups were fully alert from the start until the end of observations.
Respiratory rate
A significant (P < 0.05) net reduction of respiratory rate was observed in both groups, but there was no significant difference between two groups. The final mean respiratory rate were normal in both groups, 17.32  1.25 breath/min in T-group and 16.95  1.21 breath/min in N-group. All patients presented an increase in respiratory rate but no significant difference in respiratory rate score between two groups (P > 0.05; P = 1.000).
Mean respiratory rate at first visit were 26.63 + 1.87 breath/min in T-group and 26.47 + 1.77 breath/min in N-group. There was no significant difference between two groups (P > 0.05; P = 0.815), figure 3 . To show reduction of respiratory rate in every timeinterval we found significant reduction of respiratory rate between 0-120, then 180-240 minutes in T-group, and between 0-120, then 240-360 minutes in N-group. Until the end of observation reduction, respiratory rate was 9.32 + 2.19 (P < 0.05; P = 0.000) in T-group and was 9.53 + 1.99 (P < 0.05; P = 0.000) in N-group.
Respiratory muscle retraction (accessory muscles and suprasternal retraction)
At first time visit there was no significant difference between two groups. There were 28 (73.7%) subjects with score 1 and 10 (26.3%) subjects with score 2 in T-group, while in N-group there were 35 (92.1%) subjects with score 1 and 3 (7.9%) subjects with score 2. There was no statistical difference, P > 0.05 (P = 0.068). There was no respiratory muscle retraction in all subjects at the end of observation. T0=∑T subjects with score 0; T1=∑T subjects with score 1; T2=∑T subjects with score 2; T3=∑T subjects with score 3; N0=∑N subjects with score 0; N1=∑N subjects with score 1; N2=∑N subjects with score 2; N3=∑N subjects with score 3.
Wheeze
At first time visit there was no significant difference between the two groups. There were 1 (2.6%) subject with score 1, and 37 (97.4%) subjects with score 2 in T-group, while in N-group all subjects were score 2.
There was no statistical difference, P > 0.05 (P = 1,000). At the end of observation, all subjects were back to normal, Figure 5 . T0=∑T subjects with score 0; T1=∑T subjects with score 1; T2=∑T subjects with score 2; T3=∑T subjects with score 3; N0=∑N subjects with score 0; N1=∑N subjects with score 1; N2=∑N subjects with score 2; N3=∑N subjects with score 3.
Heart rate
At first time, visit heart rates were increased but there was no significant difference between two groups. A significant (P < 0.05) net reduction of heart rate was observed in two groups, but there was no significant difference between two groups. The final mean heart rate were normal in the two groups, 88.63  3.89 pulse/min in T-group and 88.66  3.21 breath/min in N-group. All patients presented an increase in heart rate but no significant difference in heart rate score between two groups (P > 0.05 ; P = 1.000).
Mean heart rate at first visit were 113.37  4.65 pulse/min in T-group and 113.05  5.07 pulse/min in N-group. There was no significant difference between two groups (P > 0.05; P = 0.793) figure 6 . 
PEFR
At first time visit there was no significant difference in PEFR score between two groups. All subjects in Tgroup were scored 2, while in N-group 2 (5.3%) subjects were scored 1 and 36 (94.7%) subjects were score 2 (P > 0.05; P = 0.474). At the end of observations, in T-group there were 15 (39.5%) subjects scored 0, 19 (50.0%) subjects scored 1 and 4 (10.5%) subjects scored 2. In N-group there were 19 (50.0%) subjects scored 0, 16 (42.1%) subjects scored 1 and 3 (7.9%) subjects scored 2. There was no statistical difference, P > 0.05 (P = 0.647).
First mean PEFR in T-group was 150,53 + 45,38 L/min and in N-group was 169,47 + 35,41 L/min, there was no statistical difference (P < 0,05; P = 0,055) between two groups. There was variations improvement of mean PEFR in both groups. In Tgroup the improvement kept continue until 240 minutes, then there was slight reduction until the end of observation, while in N-group improvement continued until 120 minutes, then slight reduction at 180 minutes, but rised again until the end of observation, figure 7. In T-group, we found significant improvement in every time-interval until 120 minutes, then between 180-240 minutes. There were no significant improvements in other time-intervals. In N-group, we found significant improvement in every time-interval until 60 minutes, after that there were no significant improvements until the end of observation. There was no statistical difference of PEFR improvement between two groups.
Total score of asthma attack
Mean total score of asthma attack at initial observation in T and N-groups were 10.97  0.94 and 10.79  0.78 respectively, no statistical difference (P > 0.05; P = 0.356). In both group we found significant reduction of asthma attack score at 360 minutes observation. Total score reduction in T an N-groups for 360 minutes observation were 10.26  1.13 (P < 0.05; P = 0.000) and 10.21  1.04 (P < 0.05; P = 0.000) respectively, but there was no statistical difference between two groups (P > 0.05; P = 0.834). 
Total cost
In T-group, we calculated 3,167 Rupiahs for one time inhalation, so the total of three would be 9,501 Rupiahs. We used mouthpiece to cover turbuhaler mouthpart so this device could be used to other patients. In N group the cost for using nebulizer at Persahabatan Hospital was 23,000 Rupiahs for 1 time nebulization, the cost for 1 drug was 7,000 Rupiahs, so total cost would be 90,000 Rupiahs. This is ten times more expensive than T-group. Total time used for T-group was 1 hour and 20 seconds, while for Ngroup was 1 hour and 45 minutes.
End of Observation
There were no subject needed for aminophyllin infusion or intravenous corticosteroid, because at 120 minutes observation the total score of asthma attack was less than 4.
We found 6 (15.8%) subjects in both groups with side effects. One (2.6%) subject in T-group had experienced of 3 side effects simultaneously, which were mild tremor, palpitation, and hoarseness. The rest 5 (13.2%) subjects only experienced mild tremor, while in N-group all 6 subjects experienced only mild tremor.
DISCUSSION
Seventy-six patients of moderate acute exacerbation attack with total score 8-12 enrolled this study. Age, high, weight, PEFR prediction, duration of attack were not statistically difference in both groups. Female subjects were more than male subjects, 57 (75.0%) and 19 (25.0%) subjects respectively. This was similar with Harju et al., 10 which found female patients were more often visit emergency unit because of asthma attack than male patients. Intermittent asthma was almost the same as moderate persistent asthma subjects in both groups. Sari 11 found in her study that intermittent asthma were more than persistent asthma, which were suffered from severe asthma acute exacerbation.
Susanti
12 in her study used scoring system with scale 0 to 4 to evaluate severity of asthma attack based on GINA 1998. Scoring system can help evaluating severity of asthma attack and improvement after treatment. This study used scoring system that had been used by Susanti 15 and Sari. 
APE

Turbuhaler Nebulisation
The difficulties in evaluating severity of asthma attack were described by previous studies. Clinical judgment cannot describe physiologic changes completely. In Our study, alertness was the only variable that not disturbed. Rudolf et al. 13 evaluated arterial blood gases of 14 patients with severe asthma attack whom received a standard therapeutic regime and had similar measurements made at identical time intervals under standard conditions, and performed blood gas analysis also at identical time intervals. Hypoxemia on admission was a constant finding, and the arterial oxygen tension often took a week or longer to return to a normal level. Age, duration of the acute attack, and severity of airways obstruction were all unrelated to the changes in blood gas tension, and pulse rate was found to be a poor predictor of hypoxemia in elderly asthmatics. In this study, we did not evaluated arterial blood gases because of limited budged.
Breathless was found at all subjects on admission. Mean respiratory rates on first observation were 26.63  1.87 breath/min in T-group and 26.47  1.77 breath/min in N-group, no statistical difference (P = 0.706). Sari 11 in her observation on severe asthma attack found that mean respiratory rate was 30.4 breath/min. Rodrigo 14 study showed lower respiratory rate on severe asthma attack, which were 23.3 breath/min in inhalation group and 21.5 breath/min in placebo group. This study showed that respiratory rate was unrelated to severity of asthma attack.
In severe asthma attack respiratory muscle retraction and wheeze were related to severity of obstruction. 15 In this study breathless, talking disturbance, increased respiratory rate, respiratory muscle retraction, wheeze, increased heart rate, and decreased PEFR were found in all subject. This is rather different with Sari 14 study in severe asthma attack, which showed that not all subject were suffered from alertness deterioration.
On admission mean heart rate in T-group was 113.37  4.65 pulse/min and N-group was 113.05  5.07 pulse/min, no statistical difference (P = 0.778). These values were lower than Sari 11 study but higher than Rodrigo and Rodrigo 14 study on severe asthma attack with PEFR predicted lower than 60%.
Mean PEFR on admission, T-group was 150.53 + 45.38 L/min and N-group was 169.47 + 35.41 L/min, there was no statistical difference (P = 0.055). Immediate release of bronchospasm of N-group was more superior to T-group but this was not significantly difference (P = 0.204).
This study showed that PEFR did not correlate with course therapy administered. Some of previous study showed same results. Other study evaluated drypowder inhaler (turbuhaler) and MDI with spacer, and showed no significant difference in pulmonary function and length of observation in emergency unit before discharged in both treatment. 16 Ipratropium bromide was fourth generation of atropine, which less absorbed by airway epithelial, so there is no serious side effects if use by inhalation. Bronchodilator onset of this drug is not as fast as  2 -agonist but has longer duration of action. 17 It has better bronchodilator effect if added to  2 -agonist than  2 -agonist alone and less doses of both drugs. Metaanalysis study of asthma attack showed that adding anticholinergic to β 2 -agonist will increase FEV 1 7% (100 mL) and PEFR 22% (32 mL/min). Patients who had worst airway obstruction seemed to have more advantage with this combination. 18 This has yet been fully understood why patient with severe asthma attack gave better response with ipratropium bromide. Maybe patients with severe asthma attack had more sensitive response to cholinergic. Study with children showed more consistent results with this drug. 17, 18 There is an agreement that children have more sensitive cholinergic tone to anticholinergic than adults. 17 At 5 minutes observation there were 26 (68.4%) subjects in T-group who increased more than 15% PEFR, while in N-group there were 30 (78.9%) subjects who increased PEFR more than 15%, but there was no statistical difference (P=0.435). Total subjects who had experience 15% increased PEFR were varying in every time interval in both group but there was no statistical difference. Palmqvist et al. 6 compared rapid onset of brochodilator effect of formoterol/budesonide combination with salmeterol / fluticasone and placebo. All drugs were administered using dry powder inhaler. They found that combination of formoterol/budesonide showed superior bronchodilator effect than combination of salmeterol/fluticasone or placebo.
At 40 minutes observation there were 37 (97.4%) subjects in T-group increased more than 15% PEFR, while in N-group 100% subjects did. Palmqvist et al. 6 divided 2 criteria of improvement which were 15% FEV 1 and 10% FEV 1 . After 1 hour observation they found 75% of formoterol/budesonide group and less than 50% of salmeterol/fluticasone met the first criteria, while 90% of first group and 70% of second group met second criteria.
Corticosteroid is effective as controller for asthma patients. It can improve lung function, symptoms, less visit to emergency unit, and duration of in-patient. However, study on how this drug role in asthma attack is still unclear. Some studies have shown steroids to offer benefit as early as 1 to 2 hours after administration, others question the efficacy of steroids even 12 hours or more after administration. 19 Sari 11 studied 6 hour of nebulized fluticasone compared to intravenous methylprednisolone on severe asthma attack, concluded that there was benefit in PEFR improvement, but there was no significant difference between both groups.
Combination of salbutamol/ipratropium bromide according to GINA 2004 is a continued treatment if initial treatment only give incomplete or bad response. We used this combination as a control based on Stoodley et al. 18 study which showed that this treatment had better benefit to increase PEFR than salbutamol alone. Ipratropium bromide has inferior bronchodilator effect than β 2 -agonist, but can give additional effect if combined with β 2 -agonist and is an alternative treatment for patients who have β2-agonist intolerance. 8 Mean PEFR and PEFR% predicted values that reached by both group showed significant immediate response of bronchodilator effect but no significant difference between two groups. These values also showed that until the end of observation combination of formoterol / budesonide with dry powder inhaler was comparable to combination of nebulized salbutamol/ipratropium bromide on improving lung function. This rapid onset was also shown by Palmqvist et al. 6 study which showed that 4.5/160 g formoterol/budesonide could give rapid onset in 3 minutes and doubled the doses would not give significant beneficial effect on FEV 1 .
Clinical improvement on both groups could be seen in mean total score at every time interval. Mean total score on admission in T-group was 10.97  0.94 and in N-group was 10.79  0.78, no statistical difference (P = 0.356). Total score reduction until end of observation were 10.26  1.13 in T-group and 10.21  1.04 in N-group, this reduction was statistically significant in each group (P = 0.000).
Aminophylline infusion was not needed for both groups because total score of every subject after 120 minutes was less than 4. Weinberger 20 stated that adding theophylline would not give quick benefit but after 24 hours it had benefit for severe bronchospasm. Observation on side effects, we found 6 (15.8%) subjects in each groups. One (2.6%) subject in T-group had experienced of 3 side effects which were tremor, palpitation, and hoarseness. The rest 5 (13.2%) subjects only experienced mild tremor, while in N-group all 6 subjects experienced only mild tremor. Tremor usually happens in old people, this is caused by  2-agonist stimulation on skeleton muscles. 21 Taylor et al. 22 evaluated interaction of corticosteroid with  2 -agonist, concluded that corticosteroid did not worsen cardiovascular response. Meta-analysis study from Edmonds et al. 23 showed that all treatment with corticosteroids was well tolerated, with few reports of adverse side effects, only 1 study showed mild side effect but not significant.
The cost that should be expensed in T-group was far cheaper than N-group. Total cost for three times treatment with dry powder inhaler plus mouth piece only took 9,501 Rupiahs, while for N-group needed 90,000 Rupiahs (10 x). Also N-group took time longer than T-group. Nebulized instrument will cost about 900,000 Rupiahs, maintenance and electricity will raise the cost if patients have their own devices. Turbuhaler is more practice and easier than nebulizer.
CONCLUSIONS
Combination of phormoterol/budesonide in turbuhaler
could give quick release of bronchospasm but there was no statistical difference with combination of nebulized salbutamol/ipratropium bromide in all parameter we measured. 2. There was no statistical difference in clinical improvement between both groups. 3. Treatment with drugs combination in turbuhaler was more practice and cheaper than nebulizer. 4. There were no statistical difference in efficacy and side effects in both groups.
